Scorr-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aflibercept

            Therapeutic Area: Ophthalmology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 15, 2020

            Details:

            The collaboration will research and develop an extended delivery formulation of aflibercept via the suprachoroidal space.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV vectors gene therapy

            Therapeutic Area: Ophthalmology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Harvard University

            Deal Size: $2000.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration May 11, 2020

            Details:

            CapsidMap™ enables the design of novel Adeno-Associated Virus (AAV) vectors that significantly improve upon current approaches to gene therapy and expand the scope of accessible diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PPP003

            Therapeutic Area: Ophthalmology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 15, 2020

            Details:

            Research in an experimental model of PVR has demonstrated that the synthetic cannabinoid, PPP003, can prevent this condition through activation of the type 2 cannabinoid receptor.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GtCCR4

            Therapeutic Area: Ophthalmology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Mitsubishi UFJ Capital

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 13, 2020

            Details:

            In a project under TaNeDS, Nagoya Institute of Technology discovered that a highly active, novel photoresponsive protein2 could be applied to the restoration of vision.

            Leiden University Medical Center

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HORA-001

            Therapeutic Area: Ophthalmology

            Highest Development Status: Undisclosed Product Type: Gene therapy

            Partner/Sponsor/Collaborator: Horama SA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 18, 2020

            Details:

            HORAMA will receive an exclusive worldwide license to certain patent rights and know-how for the drug candidate (referenced as HORA-001).

            Ikarovec

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Gene therapy

            Therapeutic Area: Ophthalmology

            Highest Development Status: Undisclosed Product Type: Gene therapy

            Partner/Sponsor/Collaborator: UKI2S

            Deal Size: $3.2 million Upfront Cash: Undisclosed

            Deal Type: Funding February 05, 2020

            Details:

            The cash will primarily take the company’s lead programme, a multicistronic gene therapy for diabetic macular edema (DME), to IND-enabling studies.